July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Resveratrol nanoparticles are neuroprotective in vitro suggesting a potential to cure glaucoma and Alzheimer’s disease
Author Affiliations & Notes
  • Ehtesham Shamsher
    Institute of Ophthalmology, University College London, London, United Kingdom
  • Ben Davis
    Institute of Ophthalmology, University College London, London, United Kingdom
  • Preeti Dev
    Institute of Ophthalmology, University College London, London, United Kingdom
  • Ljuban Grgic
    Institute of Ophthalmology, University College London, London, United Kingdom
  • Satyanarayana Somavarapu
    School of pharmacy, University College London, London, United Kingdom
  • Li Guo
    Institute of Ophthalmology, University College London, London, United Kingdom
  • M Francesca Cordeiro
    Institute of Ophthalmology, University College London, London, United Kingdom
    Western Eye Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships   Ehtesham Shamsher, None; Ben Davis, None; Preeti Dev, None; Ljuban Grgic, None; Satyanarayana Somavarapu, None; Li Guo, None; M Francesca Cordeiro, None
  • Footnotes
    Support  ES is supported by a University College London Overseas Research Scholarship and a Swiss Study Foundation Scholarship
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2494. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ehtesham Shamsher, Ben Davis, Preeti Dev, Ljuban Grgic, Satyanarayana Somavarapu, Li Guo, M Francesca Cordeiro; Resveratrol nanoparticles are neuroprotective in vitro suggesting a potential to cure glaucoma and Alzheimer’s disease. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2494.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Resveratrol is a natural polyphenol found in red wine and dark chocolate with potential neuroprotective effects, which could treat glaucoma and Alzheimer’s disease. However, its hydrophobicity results in a low bioavailability limiting its clinical use. To date, many groups have attempted to formulate resveratrol with limited success.

Methods : In this study, we describe the development of a new nanoparticle formulation of resveratrol that allows solubility of more than 10 mg/ml of resveratrol and is stable over 90 days when stored at room temperature. The characterisation of these nanoparticles was achieved using spectrophotometry and dynamic light scattering demonstrating no aggregation and a particle diameter lower than 22 nm.

Results : Resveratrol nanoparticles are well tolerated and protect R28 cells in vitro against cobalt chloride induced hypoxia with an IC50 (±SEM) of 938.5±127.0 µM versus 284.4 ± 35.6 µM for control group (p<0.001), glutamate induced excitoxicity with an IC50 (±SEM) of 29.32±3.00 mM versus 5.94±1.99 mM for control group (p<0.0001) and DL-homocysteine induced toxicity with an IC50 (±SEM) of 3.10±0.36 mM versus 2.05±0.06 mM for control group (p<0.05) by increasing significantly their viability in a dose-dependent manner.

Conclusions : These results show that a newly formulated resveratrol nanoparticle formulation is neuroprotective against insults known to mimic cellular stress of glaucoma and Alzheimer’s disease suggesting that it could be used to treat them. However, in vivo studies are needed to prove its efficacy further.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×